Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Eric Davis

Showing results (71-80 of 87) with videos related to

Pageof 9
Sort By:
Journal of the National Cancer Institute|December 22, 2017
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer ImmunotherapyJodi A McKenzie, Rina M Mbofung, Shruti Malu, et al.
Science Signaling|February 18, 2016
ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignanciesJo Ishizawa, Kensuke Kojima, Dhruv Chachad, et al.
Nature Communications|September 8, 2017
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genesRina M Mbofung, Jodi A McKenzie, Shruti Malu, et al.
Cancer|November 20, 2023
Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 studyMax J Gordon, Lei Feng, Paolo Strati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2022
Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell LymphomaJason Westin, R Eric Davis, Lei Feng, et al.
Blood Cancer Discovery|June 24, 2026
A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell LymphomaHaopeng Yang, Kotaro Arita, Kevin Bowman, et al.
Nature Medicine|October 6, 2020
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomasQing Deng, Guangchun Han, Nahum Puebla-Osorio, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 4, 2008
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathwaysGeorg Lenz, George W Wright, N C Tolga Emre, et al.
Cancer Cell|May 7, 2019
Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell LethalityJo Ishizawa, Sarah F Zarabi, R Eric Davis, et al.
Science Translational Medicine|June 21, 2019
Targetable genetic alterations of <i>TCF4</i> (<i>E2-2</i>) drive immunoglobulin expression in diffuse large B cell lymphomaNeeraj Jain, Keenan Hartert, Saber Tadros, et al.
Pageof 9

Showing results (71-80 of 87) with videos related to

Sort By:
Pageof 9
Journal of the National Cancer Institute|December 22, 2017
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer ImmunotherapyJodi A McKenzie, Rina M Mbofung, Shruti Malu, et al.
Science Signaling|February 18, 2016
ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignanciesJo Ishizawa, Kensuke Kojima, Dhruv Chachad, et al.
Nature Communications|September 8, 2017
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genesRina M Mbofung, Jodi A McKenzie, Shruti Malu, et al.
Cancer|November 20, 2023
Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 studyMax J Gordon, Lei Feng, Paolo Strati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2022
Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell LymphomaJason Westin, R Eric Davis, Lei Feng, et al.
Blood Cancer Discovery|June 24, 2026
A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell LymphomaHaopeng Yang, Kotaro Arita, Kevin Bowman, et al.
Nature Medicine|October 6, 2020
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomasQing Deng, Guangchun Han, Nahum Puebla-Osorio, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 4, 2008
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathwaysGeorg Lenz, George W Wright, N C Tolga Emre, et al.
Cancer Cell|May 7, 2019
Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell LethalityJo Ishizawa, Sarah F Zarabi, R Eric Davis, et al.
Science Translational Medicine|June 21, 2019
Targetable genetic alterations of <i>TCF4</i> (<i>E2-2</i>) drive immunoglobulin expression in diffuse large B cell lymphomaNeeraj Jain, Keenan Hartert, Saber Tadros, et al.
Pageof 9